Prescient Therapeutics (FRA:UDD) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Prescient Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prescient Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prescient Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Prescient Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:UDD' s Cash-to-Debt Range Over the Past 10 Years
Min: 46.99 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Prescient Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 46.99. And the median was No Debt.

FRA:UDD's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs FRA:UDD: No Debt

Prescient Therapeutics Cash-to-Debt Historical Data

The historical data trend for Prescient Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Prescient Therapeutics Cash-to-Debt Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

47.09

97.41

No Debt

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Prescient Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Prescient Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Cash-to-Debt falls into.

Prescient Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Prescient Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Prescient Therapeutics had no debt ⁽¹⁾.

Prescient Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Prescient Therapeutics had no debt ⁽¹⁾.

Prescient Therapeutics (FRA:UDD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Prescient Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (FRA:UDD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PTX:Australia

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (FRA:UDD) Headlines

No Headlines

Prescient Therapeutics (FRA:UDD) Cash-to-Debt : No Debt (1) (As of Dec. 2023)